ADMA Q4 revs ~$49-50M (+89% YoY), FY22 revs ~$153-154M (+90%); guides FY23 revs $210M+, first positive EBITDA in H2 2023

ADMA BIOLOGICS, INC.

2022-FY EPS reported -$0.33 revenue$154,079,692

Q4 2022 preliminary revs ~$49-50M, up ~89% YoY; FY22 revs ~$153-154M, up ~90% over FY21.
FY2023 revenue guidance of $210M or more, representing ~40% YoY growth.
First-time positive EBITDA expected in second half of 2023.
Plans to open tenth plasma collection center and obtain FDA licensure for three additional centers in 2023.
Long-term financial targets reiterated; current trends tracking at upper bound of expectations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADMA BIOLOGICS, INC. updated its 2023 guidance (initiated).

Period: 2023
Guidance: initiated
Result: guidance update

Exact text from the filing

ADMA currently anticipates full year 2023 total revenues of $210 million or more.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADMA BIOLOGICS, INC. reported fourth quarter and full year 2022 results: revenue preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be approximately $49-50 million. Guidance reaffirmed.

Period: fourth quarter and full year 2022
Revenue: preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be approximately $49-50 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

ADMA Biologics, Inc. (the “Company”) issued a press release announcing its preliminary unaudited fourth quarter and full year 2022 revenues and providing 2023 financial guidance.

View on SEC.gov

Browse all earnings releases →

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-23-001727

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.